A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma
Abstract Background To evaluate the effects of fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis, and the safety and tolerability of fluticasone furoate treatment in children with asthma. Methods This was a randomized, double-blind, placebo-controlled, multicenter, stratified, pa...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-02-01
|
| Series: | Allergy, Asthma & Clinical Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13223-020-0406-6 |
| _version_ | 1818575840514932736 |
|---|---|
| author | Philippe Bareille Susan Tomkins Varsha Imber Mohammed Tayob Karen Dunn Rashmi Mehta Sanjeev Khindri |
| author_facet | Philippe Bareille Susan Tomkins Varsha Imber Mohammed Tayob Karen Dunn Rashmi Mehta Sanjeev Khindri |
| author_sort | Philippe Bareille |
| collection | DOAJ |
| description | Abstract Background To evaluate the effects of fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis, and the safety and tolerability of fluticasone furoate treatment in children with asthma. Methods This was a randomized, double-blind, placebo-controlled, multicenter, stratified, parallel-group, non-inferiority study of fluticasone furoate 50 µg inhalation powder administered once daily. The study enrolled children (aged 5–11 years inclusive) with a documented diagnosis of asthma for ≥ 6 months and a Childhood Asthma Control Test score of > 19. After a 7–14-day run-in period, eligible subjects were stratified by age and randomized to fluticasone furoate 50 µg once daily or placebo once daily via ELLIPTA for 6 weeks. The primary endpoint was the change from baseline (expressed as a ratio) in 0–24-h weighted mean serum cortisol at the end of the treatment period. Results Fifty-six randomized subjects received fluticasone furoate 50 µg once daily and 55 received placebo. The primary analysis was performed in the serum cortisol population (n = 104) and demonstrated that fluticasone furoate 50 µg once daily was non-inferior to placebo (ratio = 0.93; 95% confidence interval 0.8096, 1.0620), as the lower limit of the 95% confidence interval for the geometric mean treatment ratio of fluticasone furoate 50 µg once daily versus placebo was greater than 0.80. Findings from the intent-to-treat population (n = 111) were similar. Conclusions Six weeks of treatment with inhaled fluticasone furoate 50 µg once daily had no clinically relevant effect on the hypothalamic–pituitary–adrenocortical axis function of children, as measured by 24-h serum cortisol profiles. The primary analysis showed that fluticasone furoate 50 µg once daily was non-inferior to placebo. Fluticasone furoate 50 µg once daily was well tolerated and no new safety concerns emerged during the study. Trial registration This study is registered in ClinicalTrials.gov (NCT02483975). Date of submission: 25 June 2015. |
| first_indexed | 2024-12-15T00:46:23Z |
| format | Article |
| id | doaj.art-0ce32c7bcbe24897b56dc8229228dcd6 |
| institution | Directory Open Access Journal |
| issn | 1710-1492 |
| language | English |
| last_indexed | 2024-12-15T00:46:23Z |
| publishDate | 2020-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Allergy, Asthma & Clinical Immunology |
| spelling | doaj.art-0ce32c7bcbe24897b56dc8229228dcd62022-12-21T22:41:32ZengBMCAllergy, Asthma & Clinical Immunology1710-14922020-02-011611910.1186/s13223-020-0406-6A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthmaPhilippe Bareille0Susan Tomkins1Varsha Imber2Mohammed Tayob3Karen Dunn4Rashmi Mehta5Sanjeev Khindri6Medicines Research Centre, GlaxoSmithKlineGlaxoSmithKlineGlaxoSmithKlineMzansi Ethical Research CentreNorth Carolina Clinical ResearchGlaxoSmithKline Research Triangle ParkGlaxoSmithKlineAbstract Background To evaluate the effects of fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis, and the safety and tolerability of fluticasone furoate treatment in children with asthma. Methods This was a randomized, double-blind, placebo-controlled, multicenter, stratified, parallel-group, non-inferiority study of fluticasone furoate 50 µg inhalation powder administered once daily. The study enrolled children (aged 5–11 years inclusive) with a documented diagnosis of asthma for ≥ 6 months and a Childhood Asthma Control Test score of > 19. After a 7–14-day run-in period, eligible subjects were stratified by age and randomized to fluticasone furoate 50 µg once daily or placebo once daily via ELLIPTA for 6 weeks. The primary endpoint was the change from baseline (expressed as a ratio) in 0–24-h weighted mean serum cortisol at the end of the treatment period. Results Fifty-six randomized subjects received fluticasone furoate 50 µg once daily and 55 received placebo. The primary analysis was performed in the serum cortisol population (n = 104) and demonstrated that fluticasone furoate 50 µg once daily was non-inferior to placebo (ratio = 0.93; 95% confidence interval 0.8096, 1.0620), as the lower limit of the 95% confidence interval for the geometric mean treatment ratio of fluticasone furoate 50 µg once daily versus placebo was greater than 0.80. Findings from the intent-to-treat population (n = 111) were similar. Conclusions Six weeks of treatment with inhaled fluticasone furoate 50 µg once daily had no clinically relevant effect on the hypothalamic–pituitary–adrenocortical axis function of children, as measured by 24-h serum cortisol profiles. The primary analysis showed that fluticasone furoate 50 µg once daily was non-inferior to placebo. Fluticasone furoate 50 µg once daily was well tolerated and no new safety concerns emerged during the study. Trial registration This study is registered in ClinicalTrials.gov (NCT02483975). Date of submission: 25 June 2015.https://doi.org/10.1186/s13223-020-0406-6AsthmaPediatricFluticasone furoate (FF)Safety, HPA axisSerum cortisol |
| spellingShingle | Philippe Bareille Susan Tomkins Varsha Imber Mohammed Tayob Karen Dunn Rashmi Mehta Sanjeev Khindri A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma Allergy, Asthma & Clinical Immunology Asthma Pediatric Fluticasone furoate (FF) Safety, HPA axis Serum cortisol |
| title | A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma |
| title_full | A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma |
| title_fullStr | A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma |
| title_full_unstemmed | A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma |
| title_short | A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma |
| title_sort | randomized double blind placebo controlled parallel group study of once daily inhaled fluticasone furoate on the hypothalamic pituitary adrenocortical axis of children with asthma |
| topic | Asthma Pediatric Fluticasone furoate (FF) Safety, HPA axis Serum cortisol |
| url | https://doi.org/10.1186/s13223-020-0406-6 |
| work_keys_str_mv | AT philippebareille arandomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT susantomkins arandomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT varshaimber arandomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT mohammedtayob arandomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT karendunn arandomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT rashmimehta arandomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT sanjeevkhindri arandomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT philippebareille randomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT susantomkins randomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT varshaimber randomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT mohammedtayob randomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT karendunn randomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT rashmimehta randomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma AT sanjeevkhindri randomizeddoubleblindplacebocontrolledparallelgroupstudyofoncedailyinhaledfluticasonefuroateonthehypothalamicpituitaryadrenocorticalaxisofchildrenwithasthma |